Appendix Cancer: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Appendix cancer is a rare gastrointestinal malignancy with an annual incidence of approximately 1-2 cases per 100,000 population. Unlike most cancers, appendix tumors encompass a biologically diverse group of malignancies with markedly different clinical behavior, treatment requirements, and prognoses. The major histological subtypes include: well-differentiated neuroendocrine tumors (NETs, formerly called carcinoids) — the most common type at approximately 50% of cases, often indolent and curable by appendectomy when small; low-grade mucinous appendiceal neoplasm (LAMN) — produces mucin and risks rupture causing pseudomyxoma peritonei (PMP); goblet cell adenocarcinoma (GCA) — intermediate biology between NET and adenocarcinoma, more aggressive; and colonic-type adenocarcinoma — the least common but most aggressive histological subtype, managed analogously to right-sided colorectal cancer. The majority of appendix tumors are discovered incidentally on pathological examination of appendectomy specimens removed for clinically diagnosed acute appendicitis — approximately 0.5-1% of appendectomies reveal unexpected neoplasia. Pseudomyxoma peritonei (PMP) — the dreaded complication of ruptured mucinous appendix tumors — represents the most challenging management scenario, requiring specialized cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) at expert peritoneal oncology centers, achieving 10-year survival of 60-80% when the peritoneal tumor index is favorable.

Most appendix tumors arise sporadically without identifiable environmental risk factors; hereditary syndromes account for a minority of cases. Appendiceal well-differentiated neuroendocrine tumors (NETs): originate from enterochromaffin (Kulchitsky) cells, specialized neuroendocrine cells that produce serotonin and other amines scattered throughout the appendiceal mucosa; pathogenic mechanisms involve activation of PI3K/mTOR pathway and somatostatin receptor (SSTR2 and SSTR5) expression; MEN1 syndrome (menin gene mutation on chromosome 11q13) predisposes to gastrointestinal NETs including appendiceal NETs with a higher incidence of multifocal disease; neurofibromatosis type 1 (NF1) and tuberous sclerosis are rare NET associations. Low-grade mucinous appendiceal neoplasm (LAMN): harbors KRAS mutations in approximately 50% (codons 12/13) and GNAS mutations in approximately 20%, both driving persistent mucinous differentiation and mucin overproduction; LAMN without perforation or mucin extravasation is generally low risk; LAMN with appendix perforation seeds the peritoneum, causing PMP. Goblet cell adenocarcinoma: sporadic; mixed genetic features blending NET and adenocarcinoma pathways; aggressive local behavior and early lymphovascular invasion. Colonic-type adenocarcinoma: harbors KRAS mutations (~50%), TP53 mutations, SMAD4 loss, and RAS/RAF pathway activations similar to right-sided colorectal cancer; Lynch syndrome (MSH2, MLH1, MSH6, PMS2 germline mutations) increases appendiceal adenocarcinoma risk — approximately 10-15% of appendiceal adenocarcinomas are MSI-H and respond to pembrolizumab; FAP (APC mutation) marginally increases risk.

The clinical presentation of appendix cancer is determined by tumor type, size, and whether peritoneal dissemination has occurred. Most appendix tumors are clinically silent and have no distinctive symptoms, being detected only when pathological examination of an appendectomy specimen is performed. Acute appendicitis mimicry: right lower quadrant pain (McBurney's point tenderness), low-grade fever, nausea, anorexia, and leukocytosis indistinguishable from uncomplicated appendicitis; the underlying neoplasm obstructing the appendiceal lumen precipitates this presentation; approximately 50% of appendiceal cancers present as acute appendicitis. Abdominal distension: progressive, painless abdominal enlargement — the hallmark of PMP as mucin accumulates in the peritoneal cavity; patients may initially attribute this to weight gain, IBS, or constipation, delaying diagnosis by months to years. Jelly-belly sensation: on palpation, the abdomen has a thick, doughy, non-tender consistency from intraperitoneal mucin deposits that does not shift with position changes (unlike free ascites). Adnexal or ovarian masses: bilateral mucinous ovarian involvement from PMP is common and frequently triggers erroneous primary ovarian cancer diagnosis and inappropriate surgery. Bowel obstruction: diffuse peritoneal mucin encasing bowel loops causes progressive nausea, vomiting, constipation, and eventually complete obstruction. Carcinoid syndrome: occurs exclusively when appendiceal NETs above 2 cm have liver metastases actively secreting serotonin into systemic circulation — episodic cutaneous flushing, secretory diarrhea (up to 20 stools/day), bronchospasm, and right-sided cardiac valvulopathy (tricuspid and pulmonary valve fibrosis). Advanced adenocarcinoma: constitutional weight loss, cachexia, fatigue, and features of hepatic metastasis (jaundice, right upper quadrant pain).

Diagnosis is most commonly established on histopathological examination of the appendectomy specimen by an experienced pathologist, who must assess: tumor histological type (NET, LAMN, GCA, or adenocarcinoma), size (critical threshold at 1 cm and 2 cm for NETs), Ki-67 index, margin status, lymphovascular invasion, mesoappendix invasion depth, and presence of mucin extravasation or perforation. CT abdomen/pelvis with contrast: primary imaging modality for staging — evaluates peritoneal disease extent, hepatic metastases, ovarian involvement, regional lymph nodes, and characteristic PMP features (scalloping of liver and spleen surfaces by extrinsic mucinous deposits, omental caking, peritoneal calcifications). 68Ga-DOTATATE PET-CT: highly sensitive functional imaging for somatostatin receptor-expressing well-differentiated NETs — critical for detecting occult metastases not visible on CT, especially in lymph nodes and bone; enables patient selection for 177Lu-DOTATATE PRRT. Serum tumour markers: chromogranin A (CgA) as a NET marker (elevated in approximately 60-80% of functional NETs); 24-hour urine 5-hydroxyindoleacetic acid (5-HIAA) for serotonin-secreting NETs with carcinoid syndrome; serum CEA and CA 19-9 for mucinous adenocarcinoma and LAMN. Peritoneal Cancer Index (PCI score): standardized laparoscopic or imaging-based scoring system (0-39) quantifying tumor distribution across 13 abdominal and pelvic regions — PCI below 20 generally predicts CRS/HIPEC feasibility; PCI above 25-30 is associated with high morbidity and incomplete cytoreduction. MSI/MMR testing and comprehensive NGS panel for all adenocarcinomas.

Treatment is highly individualized by histological subtype, grade, size, and peritoneal extent. Appendiceal NETs: tumors ≤1 cm — laparoscopic or open appendectomy is curative (>99% 5-year survival, no further workup required); tumors 1-2 cm — appendectomy with histological margin assessment; right hemicolectomy indicated if mesoappendix invasion exceeds 3 mm, lymphovascular invasion present, or Ki-67 above 3%; tumors above 2 cm — right hemicolectomy with minimum 12-lymph-node regional dissection; distant metastases: octreotide LAR (20-30 mg IM every 4 weeks) or lanreotide 120 mg SC for SSTR2-positive progressive NETs (CLARINET: lanreotide extended median PFS to 32.8 months); 177Lu-DOTATATE (Lutathera) PRRT for progressive SSTR2-positive NETs (NETTER-1 trial: 65.2% PFS at 20 months vs 10.8%); everolimus 10 mg/day for NET-refractory disease (RADIANT-4 trial). Goblet cell adenocarcinoma: right hemicolectomy; adjuvant chemotherapy with FOLFOX or taxol-cyclophosphamide (TC) regimen. Colonic-type adenocarcinoma: right hemicolectomy with regional lymph node dissection; adjuvant FOLFOX; MSI-H disease: pembrolizumab; KRAS wild-type metastatic disease: cetuximab or panitumumab addition. Pseudomyxoma peritonei: CRS plus HIPEC (mitomycin C 35 mg/m2 at 42-43°C for 90 minutes, or oxaliplatin 460 mg/m2) at a specialized peritoneal oncology center — achieves 10-year OS of 60-80% for low-grade PMP with PCI below 20; systemic bevacizumab plus FOLFOX/FOLFIRI for unresectable or high-PCI PMP. Low-grade LAMN without perforation: appendectomy; if perforation with mucin extravasation, staging laparoscopy and consideration of prophylactic peritoneal washout at expert centers.

Appendix cancer prognosis depends heavily on histological subtype, tumor size, and extent of peritoneal involvement. Small appendiceal NETs below 1 cm are virtually always cured by appendectomy alone, with 5-year disease-specific survival approaching 100%. NETs above 2 cm with distant metastases carry 5-year survival of approximately 50-65%, though this has improved significantly with somatostatin analogues and PRRT. Goblet cell adenocarcinoma (GCA) has 5-year survival of approximately 60-70% for localized disease, falling to approximately 25-35% with peritoneal spread. Colonic-type adenocarcinoma carries 5-year survival of approximately 45-60% overall, comparable to right-sided colorectal cancer. For pseudomyxoma peritonei (PMP) from low-grade mucinous appendix tumors, CRS plus HIPEC at specialized peritoneal oncology centers achieves remarkable outcomes: 5-year survival of approximately 80-90% and 10-year survival of 60-80% for well-selected patients with a peritoneal cancer index below 20 and complete CC-0 cytoreduction. High-grade appendiceal mucinous adenocarcinoma with peritoneal spread carries substantially worse prognosis — 5-year survival approximately 30-40% even with CRS/HIPEC. Recovery after CRS/HIPEC is prolonged, with functional recovery over 3-6 months post-surgery. Factors that improve prognosis include low tumor grade, complete cytoreduction achieving CC-0, low peritoneal cancer index, appendix primary tumor type, and treatment at high-volume specialized centers. Recurrence after curative CRS/HIPEC for PMP occurs in approximately 25-35% within 5 years; some patients are amenable to repeat intervention. Long-term quality of life is generally good for PMP survivors managed at experienced centers, with bowel function improving progressively over the first 12-24 months after surgery.

There are no established preventive measures for appendix cancer, as most tumors arise sporadically from enterochromaffin or mucosal cells without known modifiable risk factors. Patients with MEN1 syndrome require regular surveillance including abdominal imaging for appendiceal and small bowel NETs. The most important secondary prevention is ensuring complete review of appendix pathology after appendectomy — an unexpected finding of a mucinous or neuroendocrine tumor requires prompt specialist referral to determine whether additional resection or imaging is indicated. Women diagnosed with ovarian masses — particularly bilateral, mucinous ovarian masses — should have appendiceal PMP excluded before surgical planning, as misattribution to primary ovarian cancer leads to inappropriate surgery.

Unexplained progressive abdominal distension — especially in an otherwise well individual, with a jelly-like quality to abdominal fullness — should prompt evaluation for pseudomyxoma peritonei. Any individual who has had appendectomy and receives a pathology report showing a mucinous or neuroendocrine tumor should arrange prompt follow-up with a surgical oncologist rather than assuming routine post-appendectomy care is sufficient. Symptoms suggestive of carcinoid syndrome — episodes of skin flushing, watery diarrhoea, and wheezing — require evaluation for metastatic appendiceal NET secreting serotonin. New right lower abdominal pain that mimics appendicitis but resolves without clear diagnosis, or recurrent episodes, should include evaluation for an underlying appendiceal mass. Bilateral ovarian masses, particularly in younger women, should be evaluated for an appendiceal mucinous primary with peritoneal spread.